Published in

American Association for Cancer Research, Clinical Cancer Research, 4(22), p. 787-789, 2016

DOI: 10.1158/1078-0432.ccr-15-2777

Links

Tools

Export citation

Search in Google Scholar

Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism

Journal article published in 2016 by Guillaume Cartron ORCID, Roch Houot, Holbrook E. Kohrt
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Kenkre and colleagues report the absence of correlation between FcγRIIIa-V158F polymorphism and rituximab response in follicular lymphoma patients, a result which is in contrast with prior studies. This discrepancy recalls that many other factors (from the host and from the tumor) may influence the efficacy of rituximab in vivo. Clin Cancer Res; 22(4); 787–9. ©2015 AACR. See related article by Kenkre et al., p. 821